NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $258.43 -0.01 (0.00%) Closing price 03:59 PM EasternExtended Trading$259.02 +0.59 (+0.23%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Quest Diagnostics Stock (NYSE:DGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quest Diagnostics alerts:Sign Up Key Stats Today's Range$255.77▼$260.2950-Day Range$226.94▼$259.2852-Week Range$171.18▼$260.29Volume746,586 shsAverage Volume1.01 million shsMarket Capitalization$28.43 billionP/E Ratio23.41Dividend Yield1.33%Price Target$248.70Consensus RatingModerate Buy Company Overview Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research. Quest Diagnostics traces its roots to a clinical laboratory established in 1967 and became an independent company in 1996 after being spun off from Corning. It operates primarily in the United States and also has select international operations. Jim Davis serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Quest Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreDGX MarketRank™: 3.94798899515 of 5 starsQuest Diagnostics scored higher than 79% of companies evaluated by MarketBeat, and ranked 104th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingModerate Buy Consensus RatingQuest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Quest Diagnostics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageQuest Diagnostics has only been the subject of 4 research reports in the past 90 days.Read more about Quest Diagnostics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.40% Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 5.40% in the coming year, from $11.29 to $11.90 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 23.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 23.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.35.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.31. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.42% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 3.64, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 4.48%, indicating that investor sentiment is decreasing. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.33%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 34.26%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 28.91% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. News and Social Media4.3 / 5News Sentiment0.89 News SentimentQuest Diagnostics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Quest Diagnostics this week, compared to 6 articles on an average week.Search Interest10 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows3 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,715,017.00 in company stock.Percentage Held by Insiders0.88% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DGX Stock News HeadlinesWhat Happened To People Who Bought Quest Stock At A High?November 11 at 2:23 PM | finance.yahoo.comQuest Diagnostics Declares Quarterly Cash DividendNovember 10 at 4:06 PM | prnewswire.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 11 at 1:00 AM | Paradigm Press (Ad)Quest Diagnostics Inc. stock rises Monday, still underperforms marketNovember 9 at 7:41 PM | marketwatch.comQuest Diagnostics to Speak at the 9th Annual Evercore Healthcare ConferenceNovember 9 at 12:40 PM | prnewswire.comQuest Diagnostics to Speak at the Jefferies Global Healthcare Conference in LondonNovember 9 at 12:39 PM | prnewswire.comQuest Diagnostics (NYSE:DGX) EVP Sells 22,105 Shares of Company StockNovember 6, 2026 | insidertrades.comQuest Diagnostics (NYSE:DGX) Stock: Insider Gary Pfeiffer Sells 1,203 SharesOctober 29, 2026 | insidertrades.comSee More Headlines DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $173.47 at the beginning of the year. Since then, DGX shares have increased by 49.0% and is now trading at $258.43. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) posted its quarterly earnings data on Thursday, October, 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.87 by $0.13. Quest Diagnostics's revenue for the quarter was up 10.0% compared to the same quarter last year. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' Board of Directors approved a stock buyback plan on Tuesday, February 10th 2026, which allows the company to buy back $1 billion in shares, according to EventVestor. This means that the company could reacquire up to 4.7% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its shares are undervalued. Does Quest Diagnostics have any subsidiaries? The following companies are subsidiaries of Quest Diagnostics: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and more. When did Quest Diagnostics IPO? Quest Diagnostics (DGX) raised $12 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 2,300,000 shares at a price of $4.00-$6.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO. Who are Quest Diagnostics' major shareholders? Top institutional investors of Quest Diagnostics include Boston Partners (4.22%), M&G PLC (0.70%), Sumitomo Mitsui Trust Group Inc. (0.23%) and Eastern Bank (0.19%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include Pfizer (PFE), NVIDIA (NVDA), Qualcomm (QCOM), AbbVie (ABBV), Johnson & Johnson (JNJ), Tesla (TSLA) and Walmart (WMT). Company Calendar Record date for 10/21 Dividend10/06/2026Ex-Dividend for 10/21 Dividend10/06/2026Dividend Payable10/21/2026Last Earnings10/22/2026Today11/11/2026Jefferies Global Healthcare Conference11/17/20269th Annual Evercore ISI HealthCONx Conference12/01/202638th Annual Healthcare Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DGX's financial health is in the Green zone, according to TradeSmith. DGX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNYSE:DGX CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees57,000Year Founded1967Price Target and Rating Average Price Target for Quest Diagnostics$248.70 High Price Target$262.00 Low Price Target$215.00 Potential Upside/Downside-3.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$10.04 Trailing P/E Ratio23.41 Forward P/E Ratio21.72 P/E Growth2.31Net Income$992 million Net Margins9.53% Pretax Margin12.60% Return on Equity16.21% Return on Assets7.41% Debt Debt-to-Equity Ratio0.70 Current Ratio1.70 Quick Ratio1.58 Sales & Book Value Annual Sales$11.04 billion Price / Sales2.58 Cash Flow$15.17 per share Price / Cash Flow17.03 Book Value$72.26 per share Price / Book3.58Miscellaneous Outstanding Shares110,020,000Free Float109,051,000Market Cap$28.43 billion OptionableOptionable Beta0.55 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:DGX) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DGX Stock Alerts